ArticleInternational journal of clinical and experimental medicine2015
Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Impact of Renin-Angiotensin-Aldosterone System (RAAS) Gene Polymorphism in Essential Hypertension and Antihypertensive Drug Therapy: A Review.International journal of hypertension · 2025Review
- Association between Aldosterone Synthase (Genes · 2023Article
- A novel haplotype of low-frequency variants in the aldosterone synthase gene among northern Han Chinese with essential hypertension.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveA meta-analysis was carried out to evaluate the correlation between CYP11B2-344C/T polymorphism and essential hypertension susceptibility.
methodsBy retrieving relevant databases and collecting domestic and international literatures about the correlation between CYP11B2-344C/T polymorphism and essential hypertension, the quality of literature were evaluated according to NEWCASTLE-OTTAWA case-control study quality rating scale (NOS). RevMan 5.0 was used to select the best genetic model, analysis the heterogeneity, calculate combined OR and the 95% CI.
results8532 subjects were included in this study. Compared with the control group, the OR (95% CI) values of dominant model, recessive model, and additive model were 1.01 (95% CI: 0.81~1.25), 1.03 (95% CI: 0.83~1.19) and 1.10 (95% CI: 0.93-1.29).
conclusionThere is no evidence to confirm that CYP11B2 (-344C/T) polymorphism is associated with susceptibility of essential hypertension.
Indexed as
Identifiers
26309573PMC4538177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.